{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T15:38:02Z","timestamp":1794584282286,"version":"4.9.1"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,12,13]],"date-time":"2022-12-13T00:00:00Z","timestamp":1670889600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,12,13]],"date-time":"2022-12-13T00:00:00Z","timestamp":1670889600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["22J13377"],"award-info":[{"award-number":["22J13377"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["JP21am0101123"],"award-info":[{"award-number":["JP21am0101123"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["JP21am0101123"],"award-info":[{"award-number":["JP21am0101123"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001700","name":"Ministry of Education, Culture, Sports, Science and Technology","doi-asserted-by":"publisher","award":["20H00664"],"award-info":[{"award-number":["20H00664"]}],"id":[{"id":"10.13039\/501100001700","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Oncolytic adenoviruses (OAds), most of which are based on species C human adenovirus serotype 5 (Ad5) (OAd5), have recently received much attention as potential anticancer agents. High seroprevalence of anti-Ad5 neutralizing antibodies is a major hurdle for Ad5-based gene therapy. However, the impacts of anti-Ad5 neutralizing antibodies on OAd5-mediated transgene expression in the tumor and antitumor effects remain to be fully elucidated. In this study, we examined the impact of anti-Ad5 neutralizing antibodies on the OAd5-mediated antitumor effects and OAd5-mediated transgene expression. The luciferase expression of OAd-tAIB-Luc, which contains the cytomegalovirus promoter-driven luciferase gene, was inhibited in human cultured cells in the presence of human serum. Although the inhibitory effects of human serum possessing the low anti-Ad5 neutralizing antibody titers were overcome by long-term infection, the in vitro tumor cell lysis activities of OAd-tAIB-Luc were entirely attenuated by human serum containing the high titers of anti-Ad5 neutralizing antibodies. OAd-tAIB-Luc-mediated luciferase expression in the subcutaneous tumors 3\u00a0days after administration and tumor growth suppression levels following intratumoral administration were significantly lower in mice possessing the high titers of anti-Ad5 neutralizing antibodies, compared to those in control mice. These results suggested that pre-existing anti-Ad5 antibodies attenuated both transgene expression and potential antitumor effects of OAd5 following intratumoral administration.<\/jats:p>","DOI":"10.1038\/s41598-022-26030-3","type":"journal-article","created":{"date-parts":[[2022,12,13]],"date-time":"2022-12-13T17:04:10Z","timestamp":1670951050000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":25,"title":["Effects of pre-existing anti-adenovirus antibodies on transgene expression levels and therapeutic efficacies of arming oncolytic adenovirus"],"prefix":"10.1038","volume":"12","author":[{"given":"Ryosuke","family":"Ono","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fumitaka","family":"Nishimae","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takuro","family":"Wakida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fuminori","family":"Sakurai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroyuki","family":"Mizuguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,12,13]]},"reference":[{"key":"26030_CR1","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1016\/j.omto.2021.05.002","volume":"22","author":"DA Boagni","year":"2021","unstructured":"Boagni, D. A., Ravirala, D. & Zhang, S. X. Current strategies in engaging oncolytic viruses with antitumor immunity. Mol. Ther. Oncol. 22, 98\u2013113. https:\/\/doi.org\/10.1016\/j.omto.2021.05.002 (2021).","journal-title":"Mol. Ther. Oncol."},{"issue":"21","key":"26030_CR2","doi-asserted-by":"publisher","first-page":"5452","DOI":"10.3390\/cancers13215452","volume":"13","author":"MM Rahman","year":"2021","unstructured":"Rahman, M. M. & McFadden, G. Oncolytic viruses: Newest Frontier for Cancer immunotherapy. Cancers 13(21), 5452. https:\/\/doi.org\/10.3390\/cancers13215452 (2021).","journal-title":"Cancers"},{"key":"26030_CR3","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/j.cytogfr.2018.03.006","volume":"41","author":"JF de Graaf","year":"2018","unstructured":"de Graaf, J. F., de Vor, L., Fouchier, R. A. M. & van den Hoogen, B. G. Armed oncolytic viruses: A kick-start for anti-tumor immunity. Cytokine Growth Factor Rev. 41, 28\u201339. https:\/\/doi.org\/10.1016\/j.cytogfr.2018.03.006 (2018).","journal-title":"Cytokine Growth Factor Rev."},{"key":"26030_CR4","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-019-0623-z","author":"RHI Andtbacka","year":"2019","unstructured":"Andtbacka, R. H. I. et al. Final analyses of OPTiM: A randomized phase III trial of talimogene laherparepvec versus granulocyte-macrophage colony-stimulating factor in unresectable stage III\u2013IV melanoma. J. ImmunoTher. Cancer https:\/\/doi.org\/10.1186\/s40425-019-0623-z (2019).","journal-title":"J. ImmunoTher. Cancer"},{"issue":"7","key":"26030_CR5","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1038\/nrmicro1927","volume":"6","author":"R Cattaneo","year":"2008","unstructured":"Cattaneo, R., Miest, T., Shashkova, E. V. & Barry, M. A. Reprogrammed viruses as cancer therapeutics: Targeted, armed and shielded. Nat. Rev. Microbiol. 6(7), 529\u2013540. https:\/\/doi.org\/10.1038\/nrmicro1927 (2008).","journal-title":"Nat. Rev. Microbiol."},{"key":"26030_CR6","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-020-00922-1","author":"O Hemminki","year":"2020","unstructured":"Hemminki, O., dos Santos, J. M. & Hemminki, A. Oncolytic viruses for cancer immunotherapy. J. Hematol. Oncol. https:\/\/doi.org\/10.1186\/s13045-020-00922-1 (2020).","journal-title":"J. Hematol. Oncol."},{"issue":"7","key":"26030_CR7","doi-asserted-by":"publisher","first-page":"1275","DOI":"10.1038\/mt.2010.79","volume":"18","author":"S Guedan","year":"2010","unstructured":"Guedan, S. et al. Hyaluronidase expression by an oncolytic adenovirus enhances its intratumoral spread and suppresses tumor growth. Mol. Ther. 18(7), 1275\u20131283. https:\/\/doi.org\/10.1038\/mt.2010.79 (2010).","journal-title":"Mol. Ther."},{"issue":"14","key":"26030_CR8","doi-asserted-by":"publisher","first-page":"2282","DOI":"10.1016\/j.ejca.2011.12.020","volume":"48","author":"Y Yamasaki","year":"2012","unstructured":"Yamasaki, Y. et al. A novel apoptotic mechanism of genetically engineered adenovirus-mediated tumour-specific p53 overexpression through E1A-dependent p21 and MDM2 suppression. Eur. J. Cancer 48(14), 2282\u20132291. https:\/\/doi.org\/10.1016\/j.ejca.2011.12.020 (2012).","journal-title":"Eur. J. Cancer"},{"key":"26030_CR9","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1016\/j.virol.2015.04.017","volume":"483","author":"E Hastie","year":"2015","unstructured":"Hastie, E., Cataldi, M., Steuerwald, N. & Grdzelishvili, V. Z. An unexpected inhibition of antiviral signaling by virus-encoded tumor suppressor p53 in pancreatic cancer cells. Virology 483, 126\u2013140. https:\/\/doi.org\/10.1016\/j.virol.2015.04.017 (2015).","journal-title":"Virology"},{"key":"26030_CR10","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1016\/j.omto.2019.10.007","volume":"15","author":"M Zheng","year":"2019","unstructured":"Zheng, M., Huang, J., Tong, A. & Yang, H. Oncolytic viruses for cancer therapy: Barriers and recent advances. Mol. Ther Oncol. 15, 234\u2013247. https:\/\/doi.org\/10.1016\/j.omto.2019.10.007 (2019).","journal-title":"Mol. Ther Oncol."},{"issue":"6","key":"26030_CR11","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1172\/JCI9180","volume":"106","author":"T Kurihara","year":"2000","unstructured":"Kurihara, T. et al. Selectivity of a replication-competent adenovirus for human breast carcinoma cells expressing the MUC1 antigen. J. Clin. Invest. 106(6), 763\u2013771. https:\/\/doi.org\/10.1172\/JCI9180 (2000).","journal-title":"J. Clin. Invest."},{"issue":"5286","key":"26030_CR12","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1126\/science.274.5286.373","volume":"274","author":"JR Bischoff","year":"1996","unstructured":"Bischoff, J. R. et al. An adenovirus mutant that replicates selectively in p53-deficient human tumor cells. Science 274(5286), 373\u2013376. https:\/\/doi.org\/10.1126\/science.274.5286.373 (1996).","journal-title":"Science"},{"issue":"9","key":"26030_CR13","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1093\/jnci\/95.9.6522003,95(9),pp.652-60","volume":"95","author":"J Fueyo","year":"2003","unstructured":"Fueyo, J. et al. Preclinical characterization of the antiglioma activity of a tropism-enhanced adenovirus targeted to the retinoblastoma pathway. J. Natl. Cancer Inst. 95(9), 652\u2013660. https:\/\/doi.org\/10.1093\/jnci\/95.9.6522003,95(9),pp.652-60 (2003).","journal-title":"J. Natl. Cancer Inst."},{"issue":"6","key":"26030_CR14","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0002409","volume":"3","author":"I Kuhn","year":"2008","unstructured":"Kuhn, I. et al. Directed evolution generates a novel oncolytic virus for the treatment of colon cancer. PLoS ONE 3(6), e2409. https:\/\/doi.org\/10.1371\/journal.pone.0002409 (2008).","journal-title":"PLoS ONE"},{"issue":"9","key":"26030_CR15","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1093\/jnci\/95.9.652","volume":"95","author":"J Fueyo","year":"2003","unstructured":"Fueyo, J. et al. Preclinical characterization of the antiglioma activity of a tropism-enhanced adenovirus targeted to the retinoblastoma pathway. JNCI J. Natl. Cancer Inst. 95(9), 652\u2013660. https:\/\/doi.org\/10.1093\/jnci\/95.9.652 (2003).","journal-title":"JNCI J. Natl. Cancer Inst."},{"issue":"4","key":"26030_CR16","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1016\/s1535-6108(02)00060-0","volume":"1","author":"L Johnson","year":"2002","unstructured":"Johnson, L. et al. Selectively replicating adenoviruses targeting deregulated E2F activity are potent, systemic antitumor agents. Cancer Cell 1(4), 325\u2013337. https:\/\/doi.org\/10.1016\/s1535-6108(02)00060-0 (2002).","journal-title":"Cancer Cell"},{"issue":"9","key":"26030_CR17","doi-asserted-by":"publisher","first-page":"4654","DOI":"10.1128\/jvi.02696-06","volume":"81","author":"P Abbink","year":"2007","unstructured":"Abbink, P. et al. Comparative seroprevalence and immunogenicity of six rare serotype recombinant adenovirus vaccine vectors from subgroups B and D. J. Virol. 81(9), 4654\u20134663. https:\/\/doi.org\/10.1128\/jvi.02696-06 (2007).","journal-title":"J. Virol."},{"issue":"1","key":"26030_CR18","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1128\/jvi.01878-08","volume":"83","author":"AL Parker","year":"2009","unstructured":"Parker, A. L. et al. Effect of neutralizing sera on factor X-Mediated adenovirus serotype 5 gene transfer. J. Virol. 83(1), 479\u2013483. https:\/\/doi.org\/10.1128\/jvi.01878-08 (2009).","journal-title":"J. Virol."},{"issue":"22","key":"26030_CR19","doi-asserted-by":"publisher","first-page":"3837","DOI":"10.1016\/j.vaccine.2011.03.042","volume":"29","author":"C Sun","year":"2011","unstructured":"Sun, C. et al. Epidemiology of adenovirus type 5 neutralizing antibodies in healthy people and AIDS patients in Guangzhou, southern China. Vaccine 29(22), 3837\u20133841. https:\/\/doi.org\/10.1016\/j.vaccine.2011.03.042 (2011).","journal-title":"Vaccine"},{"issue":"32","key":"26030_CR20","doi-asserted-by":"publisher","first-page":"5203","DOI":"10.1016\/j.vaccine.2011.05.025","volume":"29","author":"DH Barouch","year":"2011","unstructured":"Barouch, D. H. et al. International seroepidemiology of adenovirus serotypes 5, 26, 35, and 48 in pediatric and adult populations. Vaccine 29(32), 5203\u20135209. https:\/\/doi.org\/10.1016\/j.vaccine.2011.05.025 (2011).","journal-title":"Vaccine"},{"issue":"2","key":"26030_CR21","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1016\/s0042-6822(03)00161-2","volume":"311","author":"PS Reddy","year":"2003","unstructured":"Reddy, P. S. et al. Development of adenovirus serotype 35 as a gene transfer vector. Virology 311(2), 384\u2013393. https:\/\/doi.org\/10.1016\/s0042-6822(03)00161-2 (2003).","journal-title":"Virology"},{"issue":"15","key":"26030_CR22","doi-asserted-by":"publisher","first-page":"8263","DOI":"10.1128\/jvi.77.15.8263-8271.2003","volume":"77","author":"R Vogels","year":"2003","unstructured":"Vogels, R. et al. Replication-deficient human adenovirus type 35 vectors for gene transfer and vaccination: Efficient human cell infection and bypass of preexisting adenovirus immunity. J. Virol. 77(15), 8263\u20138271. https:\/\/doi.org\/10.1128\/jvi.77.15.8263-8271.2003 (2003).","journal-title":"J. Virol."},{"issue":"4","key":"26030_CR23","doi-asserted-by":"publisher","first-page":"950","DOI":"10.1016\/j.vaccine.2009.10.145","volume":"28","author":"TC Mast","year":"2010","unstructured":"Mast, T. C. et al. International epidemiology of human pre-existing adenovirus (Ad) type-5, type-6, type-26 and type-36 neutralizing antibodies: Correlates of high Ad5 titers and implications for potential HIV vaccine trials. Vaccine 28(4), 950\u2013957. https:\/\/doi.org\/10.1016\/j.vaccine.2009.10.145 (2010).","journal-title":"Vaccine"},{"issue":"3","key":"26030_CR24","doi-asserted-by":"publisher","first-page":"1270","DOI":"10.1158\/0008-5472.CAN-05-3497","volume":"66","author":"MA Thomas","year":"2006","unstructured":"Thomas, M. A. et al. Syrian hamster as a permissive immunocompetent animal model for the study of oncolytic adenovirus vectors. Cancer Res 66(3), 1270\u20131276. https:\/\/doi.org\/10.1158\/0008-5472.CAN-05-3497 (2006).","journal-title":"Cancer Res"},{"key":"26030_CR25","doi-asserted-by":"publisher","DOI":"10.1099\/jgv.0.001752","author":"F Nishimae","year":"2022","unstructured":"Nishimae, F. et al. A dopamine antagonist, domperidone enhances the replication of an oncolytic adenovirus in human tumour cells. J. Gener. Virol. https:\/\/doi.org\/10.1099\/jgv.0.001752 (2022).","journal-title":"J. Gener. Virol."},{"issue":"1","key":"26030_CR26","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1158\/1078-0432.ccr-1075-3","volume":"10","author":"T Kawashima","year":"2004","unstructured":"Kawashima, T. et al. Telomerase-specific replication-selective virotherapy for human cancer. Clin. Cancer Res. 10(1), 285\u2013292. https:\/\/doi.org\/10.1158\/1078-0432.ccr-1075-3 (2004).","journal-title":"Clin. Cancer Res."},{"issue":"11","key":"26030_CR27","doi-asserted-by":"publisher","first-page":"1553","DOI":"10.1089\/10430340050083289","volume":"11","author":"Y Chen","year":"2000","unstructured":"Chen, Y., Yu, D. C., Charlton, D. & Henderson, D. R. Pre-existent adenovirus antibody inhibits systemic toxicity and antitumor activity of CN706 in the nude mouse LNCaP xenograft model: Implications and proposals for human therapy. Hum. Gene Ther. 11(11), 1553\u20131567. https:\/\/doi.org\/10.1089\/10430340050083289 (2000).","journal-title":"Hum. Gene Ther."},{"key":"26030_CR28","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1016\/j.jconrel.2021.02.035","volume":"332","author":"A Mato-Berciano","year":"2021","unstructured":"Mato-Berciano, A. et al. Oncolytic adenovirus with hyaluronidase activity that evades neutralizing antibodies: VCN-11. J. Control. Release 332, 517\u2013528. https:\/\/doi.org\/10.1016\/j.jconrel.2021.02.035 (2021).","journal-title":"J. Control. Release"},{"issue":"6","key":"26030_CR29","doi-asserted-by":"publisher","first-page":"1479","DOI":"10.1002\/ijc.28132","volume":"133","author":"N Hasegawa","year":"2013","unstructured":"Hasegawa, N. et al. Cyclophosphamide enhances antitumor efficacy of oncolytic adenovirus expressing uracil phosphoribosyltransferase (UPRT) in immunocompetent Syrian hamsters. Int. J. Cancer 133(6), 1479\u20131488. https:\/\/doi.org\/10.1002\/ijc.28132 (2013).","journal-title":"Int. J. Cancer"},{"issue":"5","key":"26030_CR30","doi-asserted-by":"publisher","first-page":"2130","DOI":"10.1128\/jvi.02127-08","volume":"83","author":"D Dhar","year":"2009","unstructured":"Dhar, D., Spencer, J. F., Toth, K. & Wold, W. S. M. Effect of preexisting immunity on oncolytic adenovirus vector INGN 007 antitumor efficacy in immunocompetent and immunosuppressed syrian hamsters. J. Virol. 83(5), 2130\u20132139. https:\/\/doi.org\/10.1128\/jvi.02127-08 (2009).","journal-title":"J. Virol."},{"issue":"10","key":"26030_CR31","doi-asserted-by":"publisher","first-page":"1665","DOI":"10.1038\/mt.2008.162","volume":"16","author":"MA Thomas","year":"2008","unstructured":"Thomas, M. A. et al. Immunosuppression enhances oncolytic adenovirus replication and antitumor efficacy in the Syrian hamster model. Mol. Ther. 16(10), 1665\u20131673. https:\/\/doi.org\/10.1038\/mt.2008.162 (2008).","journal-title":"Mol. Ther."},{"issue":"4","key":"26030_CR32","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1038\/cgt.2014.13","volume":"21","author":"D Dhar","year":"2014","unstructured":"Dhar, D., Toth, K. & Wold, W. S. M. Cycles of transient high-dose cyclophosphamide administration and intratumoral oncolytic adenovirus vector injection for long-term tumor suppression in Syrian hamsters. Cancer Gene Ther. 21(4), 171\u2013178. https:\/\/doi.org\/10.1038\/cgt.2014.13 (2014).","journal-title":"Cancer Gene Ther."},{"issue":"21","key":"26030_CR33","doi-asserted-by":"publisher","first-page":"7199","DOI":"10.1158\/1078-0432.ccr-04-0765","volume":"10","author":"V Tsai","year":"2004","unstructured":"Tsai, V. et al. Impact of human neutralizing antibodies on antitumor efficacy of an oncolytic adenovirus in a murine model. Clin. Cancer Res. 10(21), 7199\u20137206. https:\/\/doi.org\/10.1158\/1078-0432.ccr-04-0765 (2004).","journal-title":"Clin. Cancer Res."},{"issue":"4","key":"26030_CR34","first-page":"1145","volume":"32","author":"K Tomita","year":"2012","unstructured":"Tomita, K., Sakurai, F., Tachibana, M. & Mizuguchi, H. Correlation between adenovirus-neutralizing antibody titer and adenovirus vector-mediated transduction efficiency following intratumoral injection. Anticancer Res. 32(4), 1145\u20131152 (2012).","journal-title":"Anticancer Res."},{"key":"26030_CR35","doi-asserted-by":"publisher","DOI":"10.2147\/ijn.s27526","author":"Q Zeng","year":"2012","unstructured":"Zeng, Q. et al. Protection of adenovirus from neutralizing antibody by cationic PEG derivative ionically linked to adenovirus. Int. J. Nanomed. https:\/\/doi.org\/10.2147\/ijn.s27526 (2012).","journal-title":"Int. J. Nanomed."},{"issue":"4","key":"26030_CR36","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1038\/cgt.2010.79","volume":"18","author":"O Hemminki","year":"2010","unstructured":"Hemminki, O. et al. Oncolytic adenovirus based on serotype 3. Cancer Gene Ther. 18(4), 288\u2013296. https:\/\/doi.org\/10.1038\/cgt.2010.79 (2010).","journal-title":"Cancer Gene Ther."},{"key":"26030_CR37","doi-asserted-by":"publisher","first-page":"43","DOI":"10.2147\/ov.s155946","volume":"7","author":"TV Nguyen","year":"2018","unstructured":"Nguyen, T. V. et al. Oncolytic adenovirus Ad657 for systemic virotherapy against prostate cancer. Oncol. Virother. 7, 43\u201351. https:\/\/doi.org\/10.2147\/ov.s155946 (2018).","journal-title":"Oncol. Virother."},{"issue":"4","key":"26030_CR38","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1089\/hum.2007.124","volume":"20","author":"L Sandberg","year":"2009","unstructured":"Sandberg, L., Papareddy, P., Silver, J., Bergh, A. & Mei, Y. F. Replication-competent Ad11p vector (RCAd11p) efficiently transduces and replicates in hormone-refractory metastatic prostate cancer cells. Hum. Gene Ther. 20(4), 361\u2013373. https:\/\/doi.org\/10.1089\/hum.2007.124 (2009).","journal-title":"Hum. Gene Ther."},{"issue":"2","key":"26030_CR39","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1038\/mt.2011.242","volume":"20","author":"HH Wong","year":"2012","unstructured":"Wong, H. H. et al. Modification of the early gene enhancer-promoter improves the oncolytic potency of adenovirus 11. Mol. Ther. 20(2), 306\u2013316. https:\/\/doi.org\/10.1038\/mt.2011.242 (2012).","journal-title":"Mol. Ther."},{"key":"26030_CR40","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1016\/j.omto.2021.01.015","volume":"20","author":"R Ono","year":"2021","unstructured":"Ono, R., Takayama, K., Sakurai, F. & Mizuguchi, H. Efficient antitumor effects of a novel oncolytic adenovirus fully composed of species B adenovirus serotype 35. Mol. Ther. Oncol. 20, 399\u2013409. https:\/\/doi.org\/10.1016\/j.omto.2021.01.015 (2021).","journal-title":"Mol. Ther. Oncol."},{"issue":"5\u20136","key":"26030_CR41","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1089\/hum.2021.216","volume":"33","author":"ST Bots","year":"2022","unstructured":"Bots, S. T. et al. Nonhuman primate adenoviruses of the human adenovirus B species are potent and broadly acting oncolytic vector candidates. Hum. Gene Ther. 33(5\u20136), 275\u2013289. https:\/\/doi.org\/10.1089\/hum.2021.216 (2022).","journal-title":"Hum. Gene Ther."},{"issue":"8","key":"26030_CR42","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0041936","volume":"7","author":"MC Keefer","year":"2012","unstructured":"Keefer, M. C. et al. A phase I double blind, placebo-controlled, randomized study of a multigenic HIV-1 adenovirus subtype 35 vector vaccine in healthy uninfected adults. PLoS ONE 7(8), e41936. https:\/\/doi.org\/10.1371\/journal.pone.0041936 (2012).","journal-title":"PLoS ONE"},{"issue":"11","key":"26030_CR43","doi-asserted-by":"publisher","first-page":"3035","DOI":"10.1158\/1078-0432.ccr-09-3167","volume":"16","author":"P Nokisalmi","year":"2010","unstructured":"Nokisalmi, P. et al. Oncolytic adenovirus ICOVIR-7 in patients with advanced and refractory solid tumors. Clin. Cancer Res. 16(11), 3035\u20133043. https:\/\/doi.org\/10.1158\/1078-0432.ccr-09-3167 (2010).","journal-title":"Clin. Cancer Res."},{"issue":"21","key":"26030_CR44","first-page":"6070","volume":"62","author":"T Reid","year":"2002","unstructured":"Reid, T. et al. Hepatic arterial infusion of a replication-selective oncolytic adenovirus (dl1520): Phase II viral, immunologic, and clinical endpoints. Can. Res. 62(21), 6070\u20136079 (2002).","journal-title":"Can. Res."},{"issue":"3","key":"26030_CR45","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1089\/hum.2018.107","volume":"30","author":"M Garc\u00eda","year":"2019","unstructured":"Garc\u00eda, M. et al. A phase 1 trial of oncolytic adenovirus ICOVIR-5 administered intravenously to cutaneous and uveal melanoma patients. Hum. Gene Ther. 30(3), 352\u2013364. https:\/\/doi.org\/10.1089\/hum.2018.107 (2019).","journal-title":"Hum. Gene Ther."},{"issue":"1","key":"26030_CR46","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1158\/1078-0432.ccr-16-0477","volume":"23","author":"X Li","year":"2017","unstructured":"Li, X. et al. The efficacy of oncolytic adenovirus is mediated by T-cell responses against virus and tumor in syrian hamster model. Clin. Cancer Res. 23(1), 239\u2013249. https:\/\/doi.org\/10.1158\/1078-0432.ccr-16-0477 (2017).","journal-title":"Clin. Cancer Res."},{"issue":"4","key":"26030_CR47","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1038\/nm.3107","volume":"19","author":"Z Xu","year":"2013","unstructured":"Xu, Z. et al. Coagulation factor X shields adenovirus type 5 from attack by natural antibodies and complement. Nat. Med. 19(4), 452\u2013457. https:\/\/doi.org\/10.1038\/nm.3107 (2013).","journal-title":"Nat. Med."},{"issue":"9","key":"26030_CR48","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1038\/sj.gt.3301453","volume":"8","author":"H Mizuguchi","year":"2001","unstructured":"Mizuguchi, H. et al. A simplified system for constructing recombinant adenoviral vectors containing heterologous peptides in the HI loop of their fiber knob. Gene Ther. 8(9), 730\u2013735. https:\/\/doi.org\/10.1038\/sj.gt.3301453 (2001).","journal-title":"Gene Ther."},{"issue":"1","key":"26030_CR49","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/0042-6822(68)90121-9","volume":"36","author":"JV Maizel","year":"1968","unstructured":"Maizel, J. V., White, D. O. & Scharff, M. D. The polypeptides of adenovirus. Virology 36(1), 115\u2013125. https:\/\/doi.org\/10.1016\/0042-6822(68)90121-9 (1968).","journal-title":"Virology"},{"issue":"7","key":"26030_CR50","doi-asserted-by":"publisher","first-page":"4931","DOI":"10.4049\/jimmunol.180.7.4931","volume":"180","author":"H Sakurai","year":"2008","unstructured":"Sakurai, H. et al. Adenoviral expression of suppressor of cytokine signaling-1 reduces adenovirus vector-induced innate immune responses. J. Immunol. 180(7), 4931\u20134938. https:\/\/doi.org\/10.4049\/jimmunol.180.7.4931 (2008).","journal-title":"J. Immunol."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-26030-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-26030-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-26030-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,13]],"date-time":"2022-12-13T17:11:23Z","timestamp":1670951483000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-26030-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,13]]},"references-count":50,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["26030"],"URL":"https:\/\/doi.org\/10.1038\/s41598-022-26030-3","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,12,13]]},"assertion":[{"value":"4 August 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 December 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 December 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"21560"}}